Business, energy, technology, markets and global industry news from Business News Today

glioma

PharmaDeviceNews glioma
Brain tumour imaging advances as the US Food and Drug Administration approves Telix Pharmaceuticals’ PIXCLARA, the first FET-PET imaging agent to help distinguish glioma progression from treatment-related changes, improving precision in neuro-oncology diagnosis. Representative image.
Medical Devices & Diagnostics

Telix Pharmaceuticals wins FDA approval for PIXCLARA glioma imaging

FDA approves Telix Pharmaceuticals’ PIXCLARA, the first FET-PET drug for differentiating glioma progression from treatment-related change.

Read More
Representative image: Advanced brain PET imaging for glioma assessment, reflecting how Telix Pharmaceuticals Limited’s TLX101-Px could expand standardized FET-PET access for brain cancer diagnosis and treatment decision-making in Europe.
Medical Devices & Diagnostics

Telix just moved a brain cancer imaging asset into Europe’s regulatory fast lane

Europe needs standardized glioma PET imaging. Telix TLX101-Px now tests whether regulators and payers are ready for FET-PET access.

Read More
Pharma & Biotech

How Telix Pharmaceuticals Limited may be building a stronger neuro-oncology diagnostics franchise

Telix Pharmaceuticals Limited’s TLX101-Px NDA has been accepted by the FDA. Discover what this means for glioma imaging and the September decision.

Read More